Literature DB >> 18343513

Long-term results of stomach-conserving therapy in gastric MALT lymphoma.

Conny Vrieling1, Daphne de Jong, Henk Boot, Jan Paul de Boer, Froukje Wegman, Berthe M P Aleman.   

Abstract

PURPOSE: To evaluate long-term results of stomach-conserving therapy and to assess the value of histological probable minimal residual disease (pMRD) in predicting outcome in patients with gastric MALT lymphoma.
MATERIALS AND METHODS: We studied 115 patients with stage I-II(2) gastric MALT lymphoma treated between 1975 and 2002. Initially, first-line treatment consisted of radiotherapy only. Since 1994 most patients were primarily treated with Helicobacter pylori eradication; radiotherapy was used in case of eradication failure. To assess the value of pMRD, first follow-up biopsy samples classified as compete remission (CR) according to classical clinico-pathological criteria and biopsy samples 1 year after assessment of histological CR were reviewed; results were related to outcome.
RESULTS: Following radiotherapy only (n=56) 96% achieved a clinical CR; 10-year cancer-specific survival rate was 94%. Following H. pylori eradication only (n=35) CR-rate was 43% and after additional treatment 89%; 5-year cause-specific survival was 93%. There was no difference in relapse rate following initial histological CR or pMRD.
CONCLUSIONS: Patients with early stage gastric MALT lymphoma have a favorable long-term outcome following conservative treatment. Outcome after H. pylori eradication followed by delayed radiotherapy on indication was excellent. In our series pMRD was not associated with increased risk of recurrence.

Entities:  

Mesh:

Year:  2008        PMID: 18343513     DOI: 10.1016/j.radonc.2008.02.012

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  14 in total

1.  Splenohepatic lesions: unusual presentation of gastric lymphoma.

Authors:  Abdul Majid Wani; Waleed Mohd Hussain; Mohamad Ibrahim Fatani; Amer Mohd Khoujah; Abdullah Ahmad Tawakul; Mohannad Hemdi; Ahmed Imam
Journal:  BMJ Case Rep       Date:  2009-06-01

2.  Favorable radiation field decrease in gastric marginal zone lymphoma : Experience of the German Study Group on Gastrointestinal Lymphoma (DSGL).

Authors:  Gabriele Reinartz; Regina P Pyra; Georg Lenz; Rüdiger Liersch; Georg Stüben; Oliver Micke; Kay Willborn; Clemens F Hess; Andreas Probst; Rainer Fietkau; Ralf Jany; Jürgen Schultze; Christian Rübe; Carsten Hirt; Wolfgang Fischbach; Martin Bentz; Severin Daum; Christiane Pott; Markus Tiemann; Peter Möller; Andreas Neubauer; Martin Wilhelm; Normann Willich; Wolfgang E Berdel; Hans T Eich
Journal:  Strahlenther Onkol       Date:  2019-03-11       Impact factor: 3.621

3.  Uptake of [18F]fluorodeoxyglucose in initial positron-emission tomography predicts survival in MALT lymphoma.

Authors:  Shunan Qi; May Y Huang; Yong Yang; Heiko Schöder; Sewit Teckie; Ariela Noy; Karen Chau; Joachim Yahalom
Journal:  Blood Adv       Date:  2018-03-27

Review 4.  Treatment of gastric MALT lymphoma with a focus on Helicobacter pylori eradication.

Authors:  Qing Guo; Shanqi Guo; Yizhuo Zhang
Journal:  Int J Hematol       Date:  2013-04-25       Impact factor: 2.490

5.  Marginal zone lymphoma: old, new, targeted, and epigenetic therapies.

Authors:  Monika Joshi; Hassan Sheikh; Kamal Abbi; Sarah Long; Kamal Sharma; Mark Tulchinsky; Elliot Epner
Journal:  Ther Adv Hematol       Date:  2012-10

6.  Clinical outcomes of radiation therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma.

Authors:  Sang-Won Kim; Do Hoon Lim; Yong Chan Ahn; Won Seog Kim; Seok Jin Kim; Young Hyeh Ko; Kyoung-Mee Kim
Journal:  World J Gastroenterol       Date:  2013-09-28       Impact factor: 5.742

7.  Radiation therapy for gastric mucosa-associated lymphoid tissue lymphoma: dose-volumetric analysis and its clinical implications.

Authors:  Hyeon Woo Lim; Tae Hyun Kim; Il Ju Choi; Chan Gyoo Kim; Jong Yeul Lee; Soo Jeong Cho; Hyeon Seok Eom; Sung Ho Moon; Dae Yong Kim
Journal:  Radiat Oncol J       Date:  2016-09-28

8.  Radiotherapy for localized gastric mucosa-associated lymphoid tissue lymphoma: long-term outcomes over 10 years.

Authors:  Yu Ohkubo; Yoshihiro Saito; Hiroki Ushijima; Masahiro Onishi; Tomoko Kazumoto; Jun-Ichi Saitoh; Nobuko Kubota; Hirofumi Kobayashi; Nobuo Maseki; Yu Nishimura; Masafumi Kurosumi
Journal:  J Radiat Res       Date:  2017-07-01       Impact factor: 2.724

9.  The role of radiotherapy in the treatment of gastric mucosa-associated lymphoid tissue lymphoma.

Authors:  Taek-Keun Nam; Jae-Sook Ahn; Yoo-Duk Choi; Jae-Uk Jeong; Yong-Hyeob Kim; Mee Sun Yoon; Ju-Young Song; Sung-Ja Ahn; Woong-Ki Chung
Journal:  Cancer Res Treat       Date:  2014-01-15       Impact factor: 4.679

10.  Radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma: dosimetric comparison and risk assessment of solid secondary cancer.

Authors:  Sun Hyun Bae; Dong Wook Kim; Mi-Sook Kim; Myung-Hee Shin; Hee Chul Park; Do Hoon Lim
Journal:  Radiat Oncol J       Date:  2017-02-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.